The Medical Uses of Hydrogen
Chung, Myung-Hee, Ro, Jai Youl · Food Supplements and Biomaterials for Health · 2021
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In with T2DM controlled by diet and exercise therapy and 6 patients with IGT, they found that in hydrogen-treated animals, inflammation, apoptosis and oxidative stress were decreased whereas the production of brain-derived neurotrophic factor (BDNF) was increased. Erythema of these 4 patients and associated symptoms improved significantly after the H₂ treatment and did not recur. These findings add human evidence supporting molecular hydrogen's therapeutic potential for Alzheimer's disease.
What the Findings Mean
H2HUBB reviewed how hydrogen-rich medium affected the outcomes measured in with T2DM controlled by diet and exercise therapy and 6 patients with IGT. They found that in hydrogen-treated animals, inflammation, apoptosis and oxidative stress were decreased whereas the production of brain-derived neurotrophic factor (BDNF) was increased. Erythema of these 4 patients and associated symptoms improved significantly after the H₂ treatment and did not recur.
What the Researchers Studied
The researchers studied with T2DM controlled by diet and exercise therapy and 6 patients with IGT. The study used a randomized, double-blind, placebo-controlled, crossover human clinical trial. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 2% source-reported H₂ gas concentration; Source-reported hydrogen exposure: 2% source-reported H₂ gas concentration; reported treatment duration: 4 days. They found that in hydrogen-treated animals, inflammation, apoptosis and oxidative stress were decreased whereas the production of brain-derived neurotrophic factor (BDNF) was increased. Erythema of these 4 patients and associated symptoms improved significantly after the H₂ treatment and did not recur. 21 The intraperitoneal administration of hydrogen saline (HS) to the mice given amyloid beta protein fragments also reduced oxidative stress and inflammation, and improved memory impairment.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential for Alzheimer's disease and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized, double-blind, placebo-controlled, crossover human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was with T2DM controlled by diet and exercise therapy and 6 patients with IGT. The reported sample size was 30. The study used a randomized, double-blind, placebo-controlled, crossover human clinical trial. The hydrogen delivery method was hydrogen-rich medium. The source-reported hydrogen concentration was 2% source-reported H₂ gas concentration. The reported treatment duration was 4 days.
Limitations and Safety
Safety information: A report of 4 patients with safety data and a non-controlled feasibility study with H₂ concentration measurement on two volunteers.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base. The original scholarly source is available at https://e-fsbh.org/DOIx.php?id=10.52361/fsbh.2021.1.e5.